Disease Looks to Strike While the Climate Is Hot
Researchers Wrestle with Political Uncertainty and How It May Impact Disease Transmission
Back to School for Biotech
How Academia and Industry Can Collaborate to Advance Biologic Drug Development and Manufacturing
The Shifting Field of Stem Cell Regulations
Recent FDA Hearings Addressed Concerns Around Clinics Offering Cellular Therapies to Consumers
Enhancing Graduate and Postdoc Education for a Sustainable Workforce
Ph.D.-Trained Biomedical Scientists Can No Longer Count on Finding Academic Positions Upon Graduation
For full access to this article login to GEN Select now.
U.K. Biopharma Bouncing Back
Advantages Include 30 Leading Universities and Womb-to-Tomb Electronic Health Records
- 2012 is looking like a better year for the U.K.’s biopharm sector. Recently, a pharma heavyweight entered the ring and is banking on the region’s biomanufacturing abilities. GlaxoSmithKline recently announced an investment of over £500 million in U.K. biopharmaceutical manufacturing. Since the money is going to be spent ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.